Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SARS and Avian Flu -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (815)	5/13/2003 3:17:17 PM
From: Condor	Read Replies (1) \| Respond to of 4232

AG7708 is under development by Pfizer Inc., the pharmaceutical manufacturer, as a cold treatment and it already has reached advanced stages of clinical testing. Pfizer representatives did not respond to inquiries from United Press International. I've got to think a cold treatment would be worth some major major sales. Pfizer might be a interesting hold. Downside should be reasoanbly limited. I wonder if there's a thread or anybody is familiar with Pfizer from an investment angle? Anyone.....?